 |
Hydralazine |
|---|---|
| Trade Name | |
| Orphan Indication | Severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy |
| USA Market Approval | USA |
| USA Designation Date | 2004-04-09 00:00:00 |
| Sponsor | Bioniche Pharma USA LLC;272 E. Deerpath Road, Suite 304;Lake Forest, Illinois, 60045 |
